CorMedix, Inc. (CRMD) is making a move up in the market today. The company, focused in the biotechnology industry, is currently priced at $7.33 after a move up of 8.75% so far today. As it relates to biotech companies, there are quite a few aspects that have the potential to generate movement in the market. News is one of the most common reasons for movement. Here are the recent headlines relating to CRMD:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Nonetheless, any time investors are making an investing decision, prospective investors should focus on much more than just news, especially in the speculative biotech space. Here’s what’s going on with CorMedix, Inc..

Returns That CRMD Investors Have Seen

Although a move toward the top in a single session, like the gain that we’re seeing from CorMedix, Inc. might lead to excitement in some investors, a single session move by itself should not be the reason for a decision to, or not to, invest in a company. It is generally a good idea to look into trends just a single trading day. As it relates to CRMD, below are the trends that investors have experienced:

  • Past Seven Days – Throughout the past seven days, CRMD has seen a change in value in the amount of -0.41%.
  • Monthly – The monthly returns from CorMedix, Inc. works out to -13.25%.
  • Past Quarter – Over the past three months, the company has produced a return on investment that works out to -13.25%
  • Past Six Months – In the previous six months, we’ve seen a performance that equates to 33.27% from the stock.
  • Year To Date – Since the the last trading session of last year CRMD has resulted in a return of 13.64%.
  • Full Year – Finally, in the past year, investors have seen a change that works out to 671.58% out of CRMD. In this period, the stock has sold at a high of -46.50% and a low of 751.83%.

Ratios Of Note

Looking at various key ratios associated with a company can give prospective investors a look of how dangerous and/or rewarding a pick may be. Here are some of the important ratios to consider when looking at CRMD.

Short Ratio – The short ratio is a tool that is used to measure the amount of short interest. As the short ratio goes higher, it means that more investors have a belief that the value of the stock is going to fall. Throughout the sector, biotechnology stocks tend to have a higher short ratio. However, we also see quite a few short squeezes in the sector. Nonetheless, in relation to CorMedix, Inc., the stock’s short ratio is 7.17.

Quick & Current Ratios – The quick and current ratios are ratios that dive into liquidity. Basically, they measure the company’s abilities to pay its debts when they come due with only quick assets or current assets. Because many biotech companies rely heavily on the continuation of support from investors, these ratios can be damning. However, quite a few gems in the biotechnology space do have strong current and quick ratios. As it relates to CRMD, the quick and current ratios come to 2.30 and 2.40 respectively.  

Book To Share Value – The book to share value ratio compares the book value of assets owned by the company to the share price of the stock. In this particular case, the book to share value ratio comes in at 0.24.

Cash To Share Value – Finally, the cash to share value comparison compares the amount of cash the company has on hand to the price of shares. Several early stage biotech companies have a hard time keeping cash on hand. So, if you’re interested in a biotech stock, this is an important ratio to consider. In this case, the cash to share value ratio works out to 0.73.

What Analysts Say About CorMedix, Inc.

Although it’s never a smart idea to unknowingly follow the thoughts of analysts, it is a smart idea to use their opinions to validate your own due diligence when it comes to making investment decisions in the biotechnology sector. Here are the recent moves that we’ve seen from analysts with regard to CRMD.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-26-19 Reiterated H.C. Wainwright Buy $3 → $15
Dec-06-18 Initiated ROTH Capital Buy $6
Sep-25-17 Reiterated H.C. Wainwright Buy $3 → $4
Aug-10-17 Reiterated Rodman & Renshaw Buy $5 → $3
May-05-17 Reiterated Rodman & Renshaw Buy $6 → $5

What Are Big Money Players Doing With CorMedix, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in CRMD, here’s what we’re seeing:

Institutions own 13.80% of the company. Institutional interest has moved by 2.49% over the past three months. When it comes to insiders, those who are close to the company currently own 1.30% percent of CRMD shares. Institutions have seen ownership changes of an accumulative 195.88% over the last three months.

What’s Going On With Share Counts?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 24.18M shares of CorMedix, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, CRMD has a float of 22.76M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to CRMD, the short percent of the float is 15.34%.

Financial Performance

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-1.19. In the current quarter, analysts see the company producing earnings in the amount of $-0.29. Over the last 5 years, CRMD has generated revenue in the amount of $192.70% with earnings coming in at 15.20%. On a quarter over quarter basis, earnings have seen movement of 113.30% and revenue has seen movement of -71.30%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping An AI Become Better?

I’m an AI. So, based on what I am, I have the ability to learn by myself. Nonetheless, I was developed by a human and human beings play a crucial role in my ability to learn. Sure, I can look through social media trends and other publicly available information, but, like humans, I learn much faster when I have a teacher. If you would to teach me something, I’d love to learn! Is there other data that you’re interested in? Am I saying something wrong? Is there another way to look at information? If so, write a comment below and I will use it to serve you better!